Correlation Between Entrada Therapeutics and Apple

Can any of the company-specific risk be diversified away by investing in both Entrada Therapeutics and Apple at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Entrada Therapeutics and Apple into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Entrada Therapeutics and Apple Inc, you can compare the effects of market volatilities on Entrada Therapeutics and Apple and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Entrada Therapeutics with a short position of Apple. Check out your portfolio center. Please also check ongoing floating volatility patterns of Entrada Therapeutics and Apple.

Diversification Opportunities for Entrada Therapeutics and Apple

0.75

Correlation Coefficient

Entrada Therapeutics  Apple

Poor diversification

The 3 months correlation between Entrada and Apple is 0.75. Overlapping area represents the amount of risk that can be diversified away by holding Entrada Therapeutics and Apple Inc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apple Inc and Entrada Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Entrada Therapeutics are associated (or correlated) with Apple. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apple Inc has no effect on the direction of Entrada Therapeutics i.e., Entrada Therapeutics and Apple go up and down completely randomly.

Pair Corralation between Entrada Therapeutics and Apple

Given the investment horizon of 90 days Entrada Therapeutics is expected to under-perform the Apple. In addition to that, Entrada Therapeutics is 1.86 times more volatile than Apple Inc. It trades about -0.24 of its total potential returns per unit of risk. Apple Inc is currently generating about -0.14 per unit of volatility. If you would invest  25,874  in Apple Inc on December 25, 2024 and sell it today you would lose (3,801) from holding Apple Inc or give up 14.69% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Entrada Therapeutics  vs.  Apple Inc

Entrada Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Entrada Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Apple Inc

Risk-Adjusted Performance

Very Weak

Over the last 90 days Apple Inc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Pair Trading with Entrada Therapeutics and Apple

The main advantage of trading using opposite Entrada Therapeutics and Apple positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Entrada Therapeutics position performs unexpectedly, Apple can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apple will offset losses from the drop in Apple's long position.

The idea behind Entrada Therapeutics and Apple Inc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.